Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Zahra Mahmoudjafari, PharmD, BCOP
Authored Items
Safety of Inactivated Vaccines in Patients Receiving Immune Checkpoint Inhibitors
Austin Kurkowski, PharmD, BCOP
,
Grace A. Martin, PharmD, BCOP
,
Shelbie Ralph, PharmD, BCOP
,
Zahra Mahmoudjafari, PharmD, BCOP
,
Dennis Grauer, PhD, MS
,
Elizabeth Wulff-Burchfield, MD
JHOP - August 2021 Vol 11, No 4
in
Original Article
,
Vaccinations
,
Checkpoint Inhibitors
Myeloablative and Reduced-Intensity Preparative Regimens for Allogeneic Transplant in the Outpatient versus Inpatient Setting in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
Gretchen Pardo, PharmD
,
Beth Eddy, PharmD, BCOP
,
Zahra Mahmoudjafari, PharmD, BCOP
,
Dennis Grauer, PhD, MS
,
Joseph McGuirk, DO
JHOP - August 2021 Vol 11, No 4
in
Original Article
,
Transplant
,
Leukemia
,
Myelodysplastic Syndromes
,
Conditioning Regimen
Evaluation of Inpatient Oral Chemotherapy: An Academic Medical Center Experience
Vincent J. Cascone, PharmD, BCOP
,
Kane M. Hosmer, PharmD, BCOP
,
Zahra Mahmoudjafari, PharmD, BCOP
,
David W. Henry, MS, RPh, BCOP, FASHP
,
Dennis W. Grauer, MS, PhD
JHOP - December 2020 Vol 10, No 6
in
Original Article
,
Chemotherapy
Risk Factors for Subtherapeutic Tacrolimus Levels After Conversion from Intravenous to Oral Dosing Posttransplant in Adults
Kelsey Konrardy, PharmD
,
Kane M. Hosmer, PharmD, BCOP
,
Michelle Rockey, PharmD, BCOP, FHOPA
,
Zahra Mahmoudjafari, PharmD, BCOP
,
Dennis W. Grauer, MS, PhD
,
David W. Henry, MS, RPh, BCOP, FASHP
,
Leyla Shune, MD
,
Joseph McGuirk, DO
JHOP - June 2020 Vol 10, No 3
in
Original Article
,
Transplant
Last modified: January 15, 2021